8-K Announcements
6Material company update
Apr 29, 2026·SEC
Material company update
Feb 11, 2026·SEC
Material company update
Oct 22, 2025·SEC
Viking Therapeutics, Inc.(VKTX)Earnings, Financials & Key Ratios
VKTX•NASDAQ
Price updated Jun 19, 2026
AboutViking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.Show more
- Revenue$0
- EBITDA-$393M-160.9%
- Net Income-$360M-227.1%
- EPS (Diluted)-3.19-215.8%
- ROE-47.34%-164.5%
VKTX Key Insights
Viking Therapeutics, Inc. (VKTX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Profits declining 55.5% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when VKTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
VKTX Price & Volume
Viking Therapeutics, Inc. (VKTX) stock price & volume — 10-year historical chart
Loading chart...
VKTX Growth Metrics
Viking Therapeutics, Inc. (VKTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-268.33%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-260%
Return on Capital
10 Years-53.27%
5 Years-36.46%
3 Years-38.98%
Last Year-51.76%
VKTX Recent Earnings
Viking Therapeutics, Inc. (VKTX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)
Q2 2026Latest
Apr 29, 2026Metric
Actual
Est
EPS
$1.37-35.6%
$1.01
Rev
—
—
Q1 2026
Feb 11, 2026Metric
Actual
Est
EPS
$1.38-55.1%
$0.89
Rev
—
$2M
Q4 2025
Oct 22, 2025Metric
Actual
Est
EPS
$0.81-15.7%
$0.70
Rev
—
—
Q3 2025
Jul 23, 2025Metric
Actual
Est
EPS
$0.58-31.8%
$0.44
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 29, 2026 | $1.37vs $1.01-35.6% | — |
| Q1 2026 | Feb 11, 2026 | $1.38vs $0.89-55.1% | —vs $2M |
| Q4 2025 | Oct 22, 2025 | $0.81vs $0.70-15.7% | — |
| Q3 2025 | Jul 23, 2025 | $0.58vs $0.44-31.8% | — |
Based on last 12 quarters of dataView full earnings history →
VKTX Peer Comparison
Viking Therapeutics, Inc. (VKTX) competitors in Metabolic and Obesity Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 TERN | 4.77B | 52.95 | -51.41 | -20.02% | 0.00 | |||
 PEPG | 123.81M | 1.79 | -0.84 | -59.89% | 0.12 | |||
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 GPCR | 2.56B | 44.51 | -18.55 | -15.14% | 0.00 | |||
 CGON | 5.39B | 61.08 | -29.37 | 254.7% | -36.83% | -23.33% | 0.01 | |
 NVO | 191.93B | 43.19 | 12.18 | 6.43% | 37.2% | 66.36% | 0.67 | |
 LLY | 1.04T | 1098.13 | 47.85 | 44.7% | 34.98% | 101.17% | 1.60 | |
 AMGN | 182.2B | 337.60 | 23.72 | 9.92% | 20.95% | 89.41% | 6.31 |
Compare VKTX vs Peers
Viking Therapeutics, Inc. (VKTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
VKTX Income Statement
Viking Therapeutics, Inc. (VKTX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 260K | 0 | 0 | 0 | 0 | 0 | 431K | 208K |
COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | -260K▲ 0% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -431K▲ 0% | -208K▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - | - | - |
Gross Profit Growth % | - | - | - | 100% | - | - | - | - | - | - |
Operating Expenses | 19.07M | 26.16M | 32.43M | 42.66M | 55.68M | 70.36M | 100.83M | 150.92M | 393.34M | 502M |
OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Selling, General & Admin | 5.33M | 7.12M | 8.87M | 10.73M | 10.7M | 16.12M | 37.02M | 49.28M | 48.39M | 48.28M |
SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
Research & Development | 13.74M | 19.04M | 23.56M | 31.93M | 44.98M | 54.23M | 63.81M | 101.64M | 344.95M | 453.71M |
R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -19.07M▲ 0% | -26.16M▼ 37.2% | -32.69M▼ 24.9% | -42.66M▼ 30.5% | -55.68M▼ 30.5% | -70.36M▼ 26.4% | -100.83M▼ 43.3% | -150.92M▼ 49.7% | -393.34M▼ 160.6% | -502M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - | - | - |
Operating Income Growth % | -37.72% | -37.18% | -24.95% | -30.52% | -30.52% | -26.35% | -43.31% | -49.68% | -160.63% | - |
EBITDA | -189 | 0 | -32.43M | -42.38M | -55.39M | -70.06M | -100.53M | -150.57M | -392.91M | -501.68M |
EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
EBITDA Growth % | - | 100% | - | -30.71% | -30.67% | -26.5% | -43.49% | -49.77% | -160.94% | -191.79% |
D&A (Non-Cash Add-back) | 19.07M | 26.16M | 260K | 277K | 296K | 291K | 292K | 346K | 431K | 320K |
EBIT | -18.63M | -21.5M | -25.63M | -39.39M | -55.68M | -70.36M | -100.83M | -150.92M | -393.34M | -502M |
Net Interest Income | -1.85M | 2.71M | 6.9M | 3.13M | 685K | 1.53M | 14.93M | 40.85M | 33.7M | 29.61M |
Interest Income | 98.14K | 3.27M | 7.05M | 3.23M | 703K | 1.59M | 15.02M | 40.94M | 33.7M | 29.64M |
Interest Expense | 1.95M | 562K | 146K | 106K | 18K | 59K | 88K | 94K | 56K | 32K |
Other Income/Expense | -1.51M | 4.1M | 6.91M | 3.17M | 692K | 1.49M | 14.93M | 40.96M | 33.7M | 29.66M |
Pretax Income | -20.58M▲ 0% | -22.06M▼ 7.2% | -25.78M▼ 16.8% | -39.49M▼ 53.2% | -54.99M▼ 39.2% | -68.87M▼ 25.2% | -85.89M▼ 24.7% | -109.96M▼ 28.0% | -359.64M▼ 227.1% | -472.33M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -20.58M▲ 0% | -22.06M▼ 7.2% | -25.78M▼ 16.8% | -39.49M▼ 53.2% | -54.99M▼ 39.2% | -68.87M▼ 25.2% | -85.89M▼ 24.7% | -109.96M▼ 28.0% | -359.64M▼ 227.1% | -472.33M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - | - | - |
Net Income Growth % | -39.68% | -7.22% | -16.84% | -53.21% | -39.23% | -25.24% | -24.73% | -28.02% | -227.05% | -268.33% |
Net Income (Continuing) | -20.58M | -22.06M | -25.78M | -39.49M | -54.99M | -68.87M | -85.89M | -109.96M | -359.64M | -472.33M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.79▲ 0% | -0.38▲ 51.9% | -0.36▲ 5.3% | -0.50▼ 38.9% | -0.70▼ 40.0% | -0.88▼ 25.7% | -0.91▼ 3.4% | -1.01▼ 11.0% | -3.19▼ 215.8% | -4.09▲ 0% |
EPS Growth % | 12.22% | 51.9% | 5.26% | -38.89% | -40% | -25.71% | -3.41% | -10.99% | -215.84% | -260% |
EPS (Basic) | -0.79 | -0.38 | -0.36 | -0.50 | -0.70 | -0.88 | -0.91 | -1.01 | -3.19 | - |
Diluted Shares Outstanding | 25.98M | 57.58M | 71.96M | 72.6M | 77.2M | 76.83M | 94.35M | 109.04M | 112.67M | 115.57M |
Basic Shares Outstanding | 25.98M | 57.58M | 71.96M | 72.6M | 77.2M | 76.83M | 94.35M | 109.04M | 112.67M | 115.57M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
VKTX Balance Sheet
Viking Therapeutics, Inc. (VKTX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 21.85M | 302.13M | 283.5M | 256.1M | 210.53M | 167.04M | 367.23M | 907.22M | 715.6M | 608.21M |
Cash & Short-Term Investments | 20.58M | 301.52M | 275.64M | 248.39M | 202.1M | 155.49M | 362.08M | 902.61M | 705.74M | 602.96M |
Cash Only | 8.99M | 24.78M | 8.38M | 29.12M | 26.37M | 36.63M | 55.52M | 26.68M | 165.81M | 118.12M |
Short-Term Investments | 11.59M | 276.74M | 267.26M | 219.27M | 175.73M | 118.85M | 306.56M | 875.94M | 539.93M | 484.85M |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 388.97K | 0 | 7.46M | 7.28M | 7.81M | 8.14M | 2.52M | 1.13M | 9.86M | 1.22M |
Total Non-Current Assets | 269.61K | 179K | 755K | 399K | 134K | 1.49M | 1.26M | 1.1M | 131K | 33K |
Property, Plant & Equipment | 0 | 0 | 598K | 321K | 25K | 1.42M | 1.13M | 1M | 85K | 0 |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 269.61K | 179K | 157K | 78K | 109K | 71K | 139K | 102K | 46K | 33K |
Total Assets | 22.12M▲ 0% | 302.31M▲ 1266.6% | 284.26M▼ 6.0% | 256.5M▼ 9.8% | 210.66M▼ 17.9% | 168.53M▼ 20.0% | 368.49M▲ 118.7% | 908.32M▲ 146.5% | 715.73M▼ 21.2% | 608.24M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | 52.19% | 1266.6% | -5.97% | -9.76% | -17.87% | -20% | 118.65% | 146.5% | -21.2% | -84.78% |
Total Current Liabilities | 8.66M | 4.55M | 6.78M | 12.13M | 8.78M | 21.95M | 19.14M | 27.41M | 76.67M | 106.33M |
Accounts Payable | 1.53M | 959K | 2.43M | 3.99M | 1.44M | 8.53M | 7.51M | 9.81M | 53.25M | 67.18M |
Days Payables Outstanding | - | - | 3.41K | - | - | - | - | - | 45.1K | 57.18K |
Short-Term Debt | 3.45M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 2.28M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1.4M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 39.14M |
Current Ratio | 2.52x | 66.40x | 41.83x | 21.11x | 23.98x | 7.61x | 19.19x | 33.09x | 9.33x | 5.72x |
Quick Ratio | 2.52x | 66.40x | 41.83x | 21.11x | 23.98x | 7.61x | 19.19x | 33.09x | 9.33x | 5.72x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 4.98M | 12K | 360K | 29K | 0 | 1.26M | 936K | 630K | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 360K | 29K | 0 | 1.26M | 936K | 630K | 0 | 728K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 12K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 8.66M | 4.56M | 7.14M | 12.16M | 8.78M | 23.21M | 20.07M | 28.04M | 76.67M | 106.33M |
Total Debt | 3.45M | 0 | 662K | 359K | 29K | 1.56M | 1.26M | 1.12M | 137K | 0 |
Net Debt | -5.54M | -24.78M | -7.71M | -28.76M | -26.34M | -35.07M | -54.26M | -25.56M | -165.67M | -118.12M |
Debt / Equity | 0.26x | - | 0.00x | 0.00x | 0.00x | 0.01x | 0.00x | 0.00x | 0.00x | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.24x |
Interest Coverage | -9.55x | -38.26x | -175.57x | -371.59x | -3093.44x | -1192.46x | -1145.76x | -1605.54x | -7023.96x | -15687.44x |
Total Equity | 13.46M▲ 0% | 297.75M▲ 2111.3% | 277.12M▼ 6.9% | 244.34M▼ 11.8% | 201.88M▼ 17.4% | 145.32M▼ 28.0% | 348.42M▲ 139.8% | 880.28M▲ 152.6% | 639.06M▼ 27.4% | 501.92M▲ 0% |
Equity Growth % | 67.41% | 2111.32% | -6.93% | -11.83% | -17.38% | -28.02% | 139.76% | 152.65% | -27.4% | -103.54% |
Book Value per Share | 0.52 | 5.17 | 3.85 | 3.37 | 2.62 | 1.89 | 3.69 | 8.07 | 5.67 | 4.34 |
Total Shareholders' Equity | 13.46M | 297.75M | 277.12M | 244.34M | 201.88M | 145.32M | 348.42M | 880.28M | 639.06M | 501.92M |
Common Stock | 358 | 1K | 1K | 1K | 1K | 1K | 1K | 1K | 1K | 1K |
Retained Earnings | -80.85M | -102.92M | -128.7M | -168.19M | -223.18M | -292.05M | -377.94M | -487.91M | -847.55M | -1.01B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | -6.79M | -6.79M | 0 | 0 | 0 |
Accumulated OCI | -19.77K | -423K | 12K | -54K | -549K | -1.1M | -389K | -788K | 378K | -856K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
VKTX Cash Flow Statement
Viking Therapeutics, Inc. (VKTX) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -14.76M | -18.75M | -24.75M | -21.78M | -47.59M | -48.4M | -73.38M | -87.79M | -278.69M | -340.33M |
Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
Operating CF Growth % | -33.3% | -27.09% | -31.98% | 12.02% | -118.51% | -1.7% | -51.61% | -19.64% | -217.45% | -684.41% |
Net Income | -20.58M | -22.06M | -25.78M | -39.49M | -54.99M | -68.87M | -85.89M | -109.96M | -359.64M | -472.33M |
Depreciation & Amortization | 1.38M | 477K | 260K | 277K | 296K | 291K | 292K | 346K | 431K | -6.59M |
Stock-Based Compensation | 1.45M | 2.61M | 3.74M | 5.82M | 6.1M | 8.67M | 16.75M | 29.71M | 40.82M | 39.81M |
Deferred Taxes | -1.28M | -392K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 2.5M | -208K | 807K | 3.91M | 3.94M | 1.32M | -8.07M | -17.25M | -9.27M | 34.74M |
Working Capital Changes | 1.77M | 823K | -3.78M | 7.72M | -2.93M | 10.19M | 3.55M | 9.36M | 48.98M | 64.04M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 321K | 1.2M | 5.08M | 2.61M |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 263.51K | -508K | 1.47M | 1.55M | -2.54M | 7.08M | -1.02M | 2.3M | 43.44M | 59.48M |
Cash from Investing | -1.73M | -265.73M | 7.46M | 41.57M | 37.96M | 54.75M | -179.09M | -553.37M | 341.39M | 332.33M |
Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -1.73K | -265.73K | 0 | 0 | 0 | 54.75K | 0 | 0 | 0 | 291.68M |
Cash from Financing | 22.4M | 300.27M | 887K | 950K | 6.88M | 4.16M | 271.38M | 612.46M | 76.44M | 88.17M |
Debt Issued (Net) | -77K | -3.83M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 22.35M | 296.61M | 1.04M | 1.25M | 7.59M | -8.33M | 269.76M | 597.09M | 2.49M | 2.14M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | -6.79M | 0 | 0 | 0 | 0 |
Other Financing | 125.45K | 7.5M | -151K | -296K | -707K | 12.49M | 1.62M | 15.37M | 73.95M | 86.03M |
Net Change in Cash | 5.91M▲ 0% | 15.79M▲ 167.1% | -16.4M▼ 203.9% | 20.74M▲ 226.4% | -2.75M▼ 113.2% | 10.26M▲ 473.7% | 18.88M▲ 84.0% | -28.84M▼ 252.7% | 139.13M▲ 582.4% | 80.18M▲ 0% |
Free Cash Flow | -14.76M▲ 0% | -18.75M▼ 27.1% | -24.75M▼ 32.0% | -21.78M▲ 12.0% | -47.59M▼ 118.5% | -48.4M▼ 1.7% | -73.38M▼ 51.6% | -87.79M▼ 19.6% | -278.69M▼ 217.4% | -340.33M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - | - | - |
FCF Growth % | -33.3% | -27.09% | -31.98% | 12.02% | -118.51% | -1.7% | -51.61% | -19.64% | -217.45% | -154% |
FCF per Share | -0.57 | -0.33 | -0.34 | -0.30 | -0.62 | -0.63 | -0.78 | -0.81 | -2.47 | -2.94 |
FCF Conversion (FCF/Net Income) | 0.72x | 0.85x | 0.96x | 0.55x | 0.87x | 0.70x | 0.85x | 0.80x | 0.77x | 0.72x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
VKTX Key Ratios
Viking Therapeutics, Inc. (VKTX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -191.35% | -14.18% | -8.97% | -15.15% | -24.65% | -39.67% | -34.79% | -17.9% | -47.34% | -71.31% |
Return on Invested Capital (ROIC) | -176.97% | -13.97% | -9.04% | -13.19% | -21.35% | -36.93% | -37.4% | -19.7% | -44.42% | -67.44% |
Debt / Equity | 0.26x | - | 0.00x | 0.00x | 0.00x | 0.01x | 0.00x | 0.00x | 0.00x | 0.00x |
Interest Coverage | -9.55x | -38.26x | -175.57x | -371.59x | -3093.44x | -1192.46x | -1145.76x | -1605.54x | -7023.96x | -15687.44x |
FCF Conversion | 0.72x | 0.85x | 0.96x | 0.55x | 0.87x | 0.70x | 0.85x | 0.80x | 0.77x | 0.72x |
Related:VKTX Dividend History·VKTX Revenue History·VKTX Price History·VKTX P/E History·VKTX Financial Ratios·VKTX Institutional Holders
VKTX SEC Filings & Documents
Viking Therapeutics, Inc. (VKTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
VKTX Frequently Asked Questions
Viking Therapeutics, Inc. (VKTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Viking Therapeutics, Inc. (VKTX) grew revenue by 0.0% over the past year. Growth has been modest.
Viking Therapeutics, Inc. (VKTX) reported a net loss of $472.3M for fiscal year 2025.
Dividend & Returns
Viking Therapeutics, Inc. (VKTX) has a return on equity (ROE) of -47.3%. Negative ROE indicates the company is unprofitable.
Viking Therapeutics, Inc. (VKTX) had negative free cash flow of $340.3M in fiscal year 2025, likely due to heavy capital investments.